The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eli Merle - UBS Equities - Analyst
: Okay. Absolutely. And there's a lot of talk and we'll talk about obesity as well as match. But just in terms of the match based around having a direct
effect on the liver, particularly potentially a direct antifibrotic effect now, there's been a lot of discussion around the increments and the effects of
weight loss, which can benefit NASH, but something that I know we've spoken about in the past is some of the potential effects that Glucagon
could have specifically on the liver. So could you elaborate on this? And where you see some of the metabolic benefits on the liver?
Question: Eli Merle - UBS Equities - Analyst
: Very interesting study. And before we go more into some of the specifics of the clinical data and what you've seen so far us, going back to this
mechanism, you mentioned that you think it could have an independent effect on fibrosis in the liver, but then also we see this very potent effect
from glucagon in terms of specific liver fat reduction. Tell us a little bit more about what you think the biology behind this is?
Question: Eli Merle - UBS Equities - Analyst
: Okay. Interesting. And a question that's come up in the space around glucagon has been around safety and tolerability. We've seen some data
from served and NASH. Maybe what's your perspective, [high level] the safety tolerability profile of glucagon?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 13, 2024 / 5:30PM, ALT.OQ - Altimmune Inc at UBS Global Healthcare Conference
Question: Eli Merle - UBS Equities - Analyst
: You've highlighted sort of the balance between GLP-1 and glucagon with your molecule. Can you talk about sort of why that matters and specifically
how your molecule compares to survodutide?
Question: Eli Merle - UBS Equities - Analyst
: And I think on the surface, there was some reaction to some of the survodutide data. And thinking that some of maybe the high discontinuation
rates or some of the tolerability had to do with the glucagon component. Why do you think that's not the case?
Question: Eli Merle - UBS Equities - Analyst
: Absolutely. There's certainly a lot of different development avenues between obesity and MASH. I don't want to maybe dealienate in terms of
which trials we're talking about. But maybe first, before we dive into the clinical development strategy and the data you've seen, just high level,
how do you think about the prioritization? I mean you could theoretically be very different price points of the market the different cost structures
for developing and commercializing.
Question: Eli Merle - UBS Equities - Analyst
: Well, since it's a readout that's coming out next year in the second quarter. Let's talk about the design of your Phase 2b in NASH.
Question: Eli Merle - UBS Equities - Analyst
: And what's the reader methodology that you're using? And I know there has been some modifications towards the underrun rereading. Can you
walk us through the reader methodology?
Question: Eli Merle - UBS Equities - Analyst
: Makes sense. And something that I don't quite understand, but it seems like we've seen in a handful of trials as a weight loss medication in MASH
is a higher placebo rate. What are your expectations for your trial, both on mass resolution and fibrosis for the placebo?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 13, 2024 / 5:30PM, ALT.OQ - Altimmune Inc at UBS Global Healthcare Conference
Question: Eli Merle - UBS Equities - Analyst
: Interesting. Any color on some of the statistical assumptions?
Question: Eli Merle - UBS Equities - Analyst
: Absolutely. Let's talk about the clinical data that we've seen so far from pemvidutide, specifically walk us through the trials that you've already run
and what we've seen in terms of weight loss as well as safety tolerability.
Question: Eli Merle - UBS Equities - Analyst
: Great. And then maybe just turning to the recent interactions with and potential designs for Phase 3 and obesity. Yes. Just walk us through some
of the recent FDA feedback.
Question: Eli Merle - UBS Equities - Analyst
: And yes, I think that absolutely makes sense in terms of potential development strategy. You've mentioned that you wouldn't bring obesity forward
on your own. How should we think about the timing around the potential partnership? Are you waiting for the MAS data.
Question: Eli Merle - UBS Equities - Analyst
: Yes. And let's talk a little bit more about some of those additional indications as well that you think you can develop on your own?
Question: Eli Merle - UBS Equities - Analyst
: Great. And with ASLD this weekend, and we'll be getting the first Phase 3 readout from a GLP-1 in the space. What are you looking to see in terms
of some of the full data from the ASCENT study? And I guess also anything else that we should be focused on an ASL base?
Question: Eli Merle - UBS Equities - Analyst
: And in terms of a cash away perspective, remind us sort of where you stand from that perspective.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 13, 2024 / 5:30PM, ALT.OQ - Altimmune Inc at UBS Global Healthcare Conference
Question: Eli Merle - UBS Equities - Analyst
: Great. And again, with that, we can close it out. But thank you all so much for joining us.
| 
